REG - PureTech Health PLC - Result of AGM

Puretech HealthAnnouncement

Mon 17:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250616:nRSP0652Na&default-theme=true

RNS Number : 0652N  PureTech Health PLC  16 June 2025

16 June 2025

PureTech Health plc

 

Results of Annual General Meeting

 

The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC)
("PureTech Health" or the "Company") was held at 11 a.m. EDT/4 p.m. BST on
Monday, June 16, 2025.

 

All of the resolutions proposed at the Annual General Meeting were duly passed
by the shareholders on a poll. The results of the poll, incorporating the
proxy votes lodged in advance of the meeting, are set out below.

 

 Resolutions                                                                    For          %       Against     %       Withheld    Total votes cast
 001. To approve the Company's Annual Report and Accounts for year ended 31     161,252,066  99.97%  43,159      0.03%   43,897      161,295,225
 December 2024
 002. To approve the Directors' Remuneration Report                             87,191,034   72.49%  33,087,512  27.51%  41,060,576  120,278,546
 003. To re-elect Ms. Sharon Barber-Lui as a Director                           161,168,598  99.90%  165,990     0.10%   4,534       161,334,588
 004. To re-elect Dr. Bharatt Chowrira as a Director                            159,345,453  98.77%  1,989,135   1.23%   4,534       161,334,588
 005. To elect Dr. Michele Holcomb as a Director                                159,890,727  99.90%  153,630     0.10%   1,294,765   160,044,357
 006. To re-elect Dr. Raju Kucherlapati as a Director                           146,615,269  90.88%  14,717,819  9.12%   6,034       161,333,088
 007. To re-elect Dr. John LaMattina as a Director                              144,341,297  89.47%  16,993,291  10.53%  4,534       161,334,588
 008. To re-elect Dr. Robert Langer as a Director                               153,961,298  95.43%  7,373,290   4.57%   4,534       161,334,588
 009. To re-elect Ms. Kiran Mazumdar-Shaw as a Director                         107,562,883  72.65%  40,486,567  27.35%  13,289,672  148,049,450
 010. To reappoint PricewaterhouseCoopers LLP as Auditors of the Company        161,186,429  99.93%  110,554     0.07%   42,139      161,296,983
 011. To authorize the Audit Committee to determine the Auditors' remuneration  161,209,226  99.92%  123,862     0.08%   6,034       161,333,088
 012. To authorize the allotment of shares                                      159,323,565  99.08%  1,471,794   0.92%   543,763     160,795,359
 013. To disapply pre-emption rights                                            159,120,011  98.63%  2,216,077   1.37%   3,034       161,336,088
 014. To further disapply pre-emption rights for acquisitions and specified     157,494,464  97.95%  3,301,394   2.05%   543,264     160,795,858
 capital investments.
 015. To authorize market purchase of own shares                                159,970,124  99.15%  1,365,463   0.85%   3,535       161,335,587
 016. To authorize general meetings to be called on not less than 14 clear      161,167,825  99.91%  148,763     0.09%   22,534      161,316,588
 days' notice

 

 

While all Resolutions were passed with significant majorities, the Board notes
that Resolutions 2 and 9 received less than 80% of votes cast in favor.

The Board has consistently taken steps to proactively engage with shareholders
on remuneration and governance, including during 2024 and 2025. Consistent
with prior practice, the Board will continue to engage with shareholders in
the periods ahead and remains committed to maintaining open and constructive
dialogue. The Company will provide an update on engagement within six months
of today's Annual General Meeting, in accordance with the UK Corporate
Governance Code 2024.

Notes:

 

(1)  A vote "Withheld" is not a vote in law and is not counted in the
calculation of the votes "For" or "Against" a resolution.

 

(2)  As at June 16, 2025, the number of outstanding shares in the Company was
240,254,449 ordinary shares, which was the total number of shares entitling
the holders to attend and vote for or against all the resolutions at the
AGM.  In accordance with the Company's Articles of Association, on a poll
every member present in person or by proxy has one vote for every share held.

 

(3)  The full text of the resolutions may be found in the Notice of the
Annual General Meeting, copies of which are available on both the Company's
website https://investors.puretechhealth.com/financials-filings/reports and on
the National Storage Mechanism.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep portfolio through its
experienced research and development team and its extensive network of
scientists, clinicians, and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 29 therapeutics and therapeutic candidates,
including three that have been approved by the U.S. Food and Drug
Administration. A number of these programs are being advanced by PureTech or
its Founded Entities in various indications and stages of clinical
development, including registration-enabling studies. All of the underlying
programs and platforms that resulted in this portfolio of therapeutic
candidates were initially identified or discovered and then advanced by
the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X (formerly Twitter)
@puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statement that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation statements that relate to our expectations around
our therapeutic candidates and approach towards addressing major diseases, our
future prospects, developments, and strategies. The forward-looking statements
are based on current expectations and are subject to known and unknown risks,
uncertainties and other important factors that could cause actual results,
performance and achievements to differ materially from current expectations,
including, but not limited to, those risks, uncertainties and other important
factors described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2024 filed with the SEC and in our
other regulatory filings. These forward-looking statements are based on
assumptions regarding the present and future business strategies of the
Company and the environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press release.
Except as required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGPKABBABKDOAD